Despite concerns that Medicare Advantage payment reductions included in the Affordable Care Act would lead to a decline in enrollment, the number and share of beneficiaries enrolling in Medicare Advantage has only continue to climb since the health reform law was enacted.
Medicare Advantage (MA) payment reductions that were included in the Affordable Care Act were controversial, with some concerned that the cuts would lead to a decline in enrollment in MA; however, since the enactment of the health reform law, the number and share of Medicare beneficiaries enrolling in MA has only continued to climb, according to a report from the Kaiser Family Foundation.
Since 2010, enrollment in MA has increased by 50%, and from 2014 to 2015 enrollment grew by more than 1 million beneficiaries, or 7%. There are now a total of 16.8 million beneficiaries, or 31% of the overall Medicare population, enrolled in MA plans.
“From the perspective of the Medicare program overall, it is clear that Medicare Advantage has become an increasingly important way in which Medicare beneficiaries receive their benefits and all signs suggest that this will only increase in the future,” the authors of the report wrote.
South Dakota and North Dakota saw particularly large increases in enrollment (19% and 18%, respectively). However, MA penetration in these states is relatively low. For example, the average state penetration rate is 31%, with Minnesota have the highest rate at 53%, followed by Hawaii (46%) and Oregon (44%). In comparison, Alaska has the lowest penetration rate with less than 1% of Medicare enrollees are in MA plans, followed by Wyoming (2%).
“While Medicare Advantage premiums have remained relatively flat, out-of-pocket limits have been increasing over the past few years, providing less financial protection to Medicare enrollees with significant medical needs than they have in the past,” the authors wrote in the report.
Monthly premiums for MA prescription drug plans increased $3 per month to $38 (7% increase), but premiums do vary across plan types and states. The share of enrollees in MA prescription drug plans with $0 premiums declined from 56% to 48%. Premiums also vary greatly by state. While the national average is $38, average monthly premiums are highest in Massachusetts ($107), Michigan ($93), Minnesota ($130), and Pennsylvania ($94) and lowest in Florida ($6), Nevada ($13), Arizona ($15), Louisiana ($15), and Iowa ($15).
The average out-of-pocket spending limits has risen to $5041. All plans are required to limit these expenses to no more than $6700.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More